Registration

Day 1: Thursday August 24, 2023

09:45-10:00:    Welcome and Opening: Bjørn Tore Gjertsen (Chair, Nordic AML Group)

Session 1: Chairs: Bjørn Tore Gjertsen, Jeffrey Tyner

10:00-10:30:    NAMLG Keynote Lecture

                           Sören Lehmann: Chromatin organization – the next step in the characterization of AML

10:30-10:50:    Jorrit Enserink: Drug sensitivity Screen in AML undergoing intensive chemotherapy

10:50-11:10:    Krister Wennerberg: Repurposing through drug sensitivity screen in AML

11:10-11:30:    Caroline Heckman: Contextual factors in drug sensitivity screen

11:30-11:50:    Päivi Östling: Harmonization of Drug sensitivity Screen

Session 2: Chair: Mika Kontro, Kim Theilgaard-Mönch

11:50-12:20:    Martin Jädersten: Real world use of venetoclax

12:20-12:40:    Kim Theilgaard-Mönch: Interim analysis of the NAMLG trial LD-VenEx

12:40-13:30:    NAMLG Keynote Lecture

                           Daniel A Pollyea: Venetoclax in AML: Current state of the art and future development

13:30-14:30:   LUNCH BREAK

Session 3: Chairs: Sören Lehmann, Oscar Brück

14:30-14:50:    Tom Erkers: Data driven hallmarks in AML

14:50-15:10:    Thoas Fioretos: Harnessing the Power of Genomics for Improved  Precision Medicine                                               

15:10-15:40    COFFEE BREAK

Session 4: Chairs: Bjørn Tore Gjertsen, Karl-Johan Malmberg 

15:40-16:10:    Mohn Research Centre for Regenerative Medicine (MRCRM) Keynote Lecture

                           Gunnar Kvalheim: WT1/PRAME RNA-loaded dendritic cell vaccine in AML

16:10-16:30:   Karl-Johan Malmberg: NK immunotherapy in AML

16:30-16:50:    Sébastien Walchli: CAR T in AML

18:10-19:15 RECEPTION IN HAAKONSHALLEN, BERGEN MUNCIPALITY

19:45            CONFERENCE DINNER

______________________________________________________________________

Day 2: Friday August 25, 2023

Session 5: Chairs: Anne-Sophie von Krogh, Marianne Tang Severinsen

08:15-08:45:     Gunnar Juliusson: Challenges of the new AML classifications and guidelines

08:45 – 09:00:  Discussion

09:00 – 09:30:  NAMLG Keynote Lecture

                             Gerwin Huls: AML therapy backbone and the future of targeted therapies

09:30 – 09:50: Hans Beier Ommen: Measurable residual disease monitoring

09:50 – 10:10:  Marianne Tang Severinsen: Registries in AML and a Nordic cohort of AML

10:10 – 10:40:  Oscar Brück: Data Lake and collection of data for real world epidemiology

10:40 – 11:10 COFFEE BREAK

Session 6: Chairs: Caroline Heckman, JJ Schuringa

11:10 – 11:40:  NAMLG Keynote Lecture

                           J.J. Schuringa: Tumor-stromal interactions in AML

11:40 – 12:00:  Mika Kontro: Novel macrophage re-programmer bexmarilimab in myeloid malignancies

12:00 –12:30:  CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB

                            Jeffrey Tyner: Big data for novel therapeutic strategies in myeloid malignancies

12:30 – 13:30: LUNCH BREAK

Session 7: Chairs: James Lorens, Krister Wennerberg

13:30 – 13:45: James Lorens: Axl as therapeutic target in cancer

13:45 – 14:15: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB

                          Sonia Loges: AXL in AML

14:15 – 14:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB 

                          Uwe Platzbecker: Bemcentinib and Axl in MDS and AML.

Session 8: Chairs: Jean Christoph Bourdon; Andrea Lenartova

14:45 – 15:05: Jean Cristoph Bourdon: p53 and its isoforms in cancer

15:05 – 15:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB

                          Eva Hellström-Lindberg: TP53 mutations in MDS and AML

15:45 – 16:15 COFFEE BREAK

Session 9: Chair: Pia Ettala, Vladimir Lazarevic

16:15 – 16:45:  Martin Höglund: The therapeutic landscape in the Nordics: fit and unfit patients in a regional collaboration

16:45 – 17:00: Closing remarks: Mika Kontro, Secretary, NAMLG

Registration